Annual General Meeting of Q-Med AB (publ)

The Board of Directors of Q-Med AB (publ) has of today published a notice to
attend the Annual General Meeting, which will be held on Wednesday April 28 at
3 p.m. on Q-Med's premises.Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A
notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in Post-
och Inrikes Tidningar (Swedish Official Gazette). The complete notice of the
Annual General Meeting in English can be found on the corporate web site
www.q-med.com <http://www.q-med.com/>, and is also attached.

Q-Med AB (publ)

The Board


Queries should be addressed to:
Kristin Ermanbriks, Manager Corporate Administration
Tel: +46 70 974 9071



Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA(TM), for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta(TM) for the treatment of fecal incontinence. Sales are made through
the company's own subsidiaries or distributors in over 70 countries. Q‑Med today
has about 650 coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of the NASDAQ OMX Nordic.



Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden.Corporate identity
                              number 556258-6882.
      Tel: +46 18 474 90 00. Fax: +46 18 474 90 01.E-mail: info@q-med.com
      <mailto:info@q-med.com>. Web: www.q-med.com <http://www.q-med.com/>.



[HUG#1398086]